ASSESSING HOME DELIVERY MODEL OPTION FOR IMPROVING ACCESS TO ANTIRETROVIRAL THERAPY; PROTOCOL FOR A CLUSTER- RANDOMIZED TRIAL IN ANAMBRA STATE, NIGERIA.

Ajagu Nnenna^{1,2}, Offu Ogochukwu^{1,2}, Nduka Sunday¹, Ekwunife Ikechukwu Obinna^{1,2}

ARHD Trial - *Antiretroviral Home Delivery Trial*

Author information

Ajagu Nnenna (Msc.) ajagunnenna@yahoo.com, nnennaajagu@esut.edu.ng

Offu Ogochukwu (Msc.) offu.ogochukwu@esut.edu.ng, ogoffu@gmail.com

Nduka Sunday (PhD) so.nduka@unzik.edu.ng

Ekwunife Obinna (PhD) oi.ekwunife@unzik.edu.ng, oekwunife@gmail.com

Authors Affiliations:

¹Department of Clinical Pharmacy and Pharmacy Management, Nnamdi Azikiwe University, Awka, Nigeria

²Department of Clinical Pharmacy and Biopharmaceutics, Enugu State University of Science and Technology, Agbani, Nigeria.

Corresponding author:

Ajagu Nnenna ajagunnenna@yahoo.com, nnennaajagu@esut.edu.ng

+2348035460931 Department of Clinical Pharmacy and Pharmacy Management, Nnamdi Azikiwe University, Awka, Nigeria and Department of Clinical Pharmacy and Biopharmaceutics, Enugu State University of Science and Technology, Agbani, Nigeria.

ABSTRACT

Background: Although different antiretroviral (ARV) agents' delivery models have been explored in Nigeria, yet only about 55% and 35% of affected adults and children respectively are currently on these agents. This, therefore, underscores the need for the identification of newer effective antiretroviral therapy delivery models and best strategies to increase access to ARV therapy in Nigeria. **Method and Analysis:** The study

will be a cluster randomized controlled trial, which will be conducted in two HIV treatment centers in Anambra State, Nigeria. Participants will be randomized into intervention and control arm. Home delivery personnel will be trained to deliver the ARV drugs at 3months intervals to the homes of those in the intervention group while those in the control group (Facility-based services group) will receive ARVs at the HIV treatment hospital. The primary outcome for the trial will be the difference between groups in the proportion with HIV viral load suppression (≤ 20 copies/mL) by 12 months and then 24months. Secondary outcome include adherence to ARVs, the cost-effectiveness of home delivery service, and patient satisfaction.

Ethics and dissemination: *Nnamdi Azikiwe University Teaching Hospital Health Research Ethics Committee (NAUTHHREC) approved this study (NAUTH/CS/66/VOL.13/VER III/23/2020/011) with a trial registration: Pan African Clinical Trials Registry, ID: PACTR202004535536808 on 8th April 2020. Study dissemination plans include holding advocacy meetings with stakeholders in HIV care, publishing study outcomes in an open-access peer-review journal, and presentation of the outcome at an international conference.*

Words: 234

Keywords:

Antiretroviral, HIV, Home delivery, Nigeria.

Strength and Limitations of this study:

- This is the first randomized trial assessing the effectiveness of the home delivery model of antiretroviral therapy.
- The primary outcome in this trial will be measured by assessing the difference between baseline HIV viral load and 12/24 months in both the intervention and control arm.
- In this study, patients will be assigned to treatment groups and non-treatment groups. This will help us to compare the effect of the home delivery model.

- In this study, only one state in Nigeria and two HIV/AIDS treatment hospitals in the state will be used to access the impact of the home delivery model. This may not allow for the generalization of the study findings.
- This study could serve as a pilot to a full-fledged national study to access the effectiveness of the home delivery model.

INTRODUCTION

We owe approximately 39 million people who have died of HIV/AIDS the significant obligation to eradicate the disease. Additionally, eradication of this disease represents a tremendous opportunity to lay the foundation for a healthy world for the future generation (1). Unfortunately, the morbidity and mortality rate from HIV/AIDS is still high (2) due to some important reasons including poor access to highly active antiretroviral therapy (HAART) (2).

Poor access and adherence to the HAART has a significant impact on the overall treatment outcomes because of the chronic nature of the disease (3). Hence, continuous access to HIV treatment is very important to achieving a successful positive response to this public health issue (2).

It is the right of everyone including people living with HIV to have equitable access to the drugs as contained in sustainable development goals (SDGs) (4), and the right to equitable health is linked to one of the targets set by the Joint United Nations Programme on HIV and AIDS (UNAIDS) for ending HIV in the year 2030. According to this target, at least 95% of people living with HIV should have access to antiretroviral agents (5) as this is strategic to achieving the clinical, immunologic, and virologic goals of HIV/AIDS treatment. Ultimately, ending HIV can only be achieved when the right to access drugs is placed at the center of the public health campaign to end HIV (6).

About 36.9 million people are living with HIV/AIDS globally and only about 59% of this population had access to ARV according to the 2019 UNAIDS factsheet (7). Whereas Africa constitutes about 67% of the

global disease burden(8) and with about 1.9 million of them living in Nigeria with a prevalence rate of 1.4 %(9), only 55% and 35% of the affected adults and children respectively had access to ART in 2018 (10). Hence, the identification of new strategies to increase access to ARV agents should be an urgent priority (11).

In 2016, the World Health Organization (WHO) modified its CD4 cell count threshold in the treatment guidelines and recommended a test-and-treat strategy for all persons living with HIV (12). This development substantially increased the number of people on ART (13) with an increasing cohort of stable patients which may constitute a huge burden to the already burdened health system, especially in most developing countries. Therefore the development of new and innovative ways to increase access to antiretroviral therapy that would decongest health facilities while supporting the SDG goals is of utmost importance.

A semi-structured interview carried out by Hardon et al in 2007(14) in health facilities in Uganda, Tanzania and Botswana identified convenience, long waiting times to receive care, and transportation cost as challenges to achieving optimal care in HIV/AIDS management. A study by Cunningham et al., (15) in the US, reported the cost of transport to the treatment site and the inability to get out of work as important barriers to accessing ART. Similarly in Nigeria, long distances to the service delivery points, transport costs, as well as long waiting times have been identified as barriers to accessing antiretroviral agents in the country (16). Meanwhile, a study by Jaffar et al. (11) that compared rates of virologic failures in patients treated at home as against those treated in the facility (hospital) found no significant difference between the two.

Different strategies to improve access to ARVs in Nigeria have been suggested by the Strengthening Integrated Delivery of Services on HIV/AIDS (SIDSHAS) projects and currently in their pilot stage. Among these strategies are the Community Antiretroviral Refill Club (CARC) for patients living in remotes areas with a particular interest in the riverine areas and the Community Pharmacy Antiretroviral Refill

Programme (C-PARP)(17). These programs are targeted at reducing visits to the hospitals by stable clients to decongest the facilities which come with several other benefits.

Meanwhile, a theoretical foundation underlines the delivery of antiretroviral to patients' homes as a way of improving both adherence and viral load, as seen in the HUB and SPOKES model of differentiated care, where centers provide specialized services through established linkages with several secondary facilities within a network and patients are referred to for specialized services when the indications for such arises (18–21). Services provided at this level include HCT, ARV re-fill, adherence counseling, and treatment of simple opportunistic infections (OIs) (18–21). This could serve as a current focus strategy for improving access to ARVs. The practical benefit of this approach is a significant reduction in the pharmacy waiting time while decongesting the healthcare facilities. This approach has been successfully applied in some facilities in the UK (22) and hence, it looks like a promising strategy to achieving improved access to ARVs in resource-limited settings. This study, therefore, aims to assess the possibility of using a home-based antiretroviral delivery model and as a new strategy for increasing access to antiretroviral agents in resource-limited settings.

METHODS AND ANALYSIS

Study design

This study will utilize a cluster-randomized trial approach to evaluate the effectiveness of antiretroviral home delivery strategy on HIV/AIDS treatment outcomes with a focus on improving access to the ARV agents. Based on the information we received at the time of conducting this study, only 12 hospitals in Anambra State offer comprehensive HIV services including HIV-adherence counseling and antiretroviral treatment services. Two hospitals among the 12 comprehensive HIV treatment hospitals that have high HIV/AIDS patients' base were randomly selected. Patients that meet the inclusion criteria in these two hospitals will be randomly assigned to intervention or control (see fig 1).

Study setting

The study setting will be in Anambra state which is one of the five states in the Southeast geopolitical zone in Nigeria. It is bounded in the northeast by Enugu state, in the east by Enugu and Abia states, in the west by Delta state while in the South and Northwest by Imo and Kogi states respectively. The State is mainly inhabited by Igbo-speaking people who are mostly Christians. Most members of the population are farmers, civil servants, artisans, and businessmen, and women (23); with a projected population of approximately 4,177,828 (50.7% males and 49.3% females) (24). Interestingly, about 60.5% of these populations are of ages 15-65 years (25). Awka is the state's capital and there are 21 local government areas in the state out of which five are urban; five are semi-urban while eleven are rural (23). Anambra state is made up of 21 local government areas with an HIV prevalence rate of 2.4% (25). There are about 1,485 health facilities in the state including two tertiary and 31 public health facilities, with private hospitals constituting about 75% of the health facilities (26).

Intervention

Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and they will consent to the study by signing the consent form (see Fig 3). Those that give their consent will be sent to the physician after collecting information that will aid home delivery of their drugs including delivery points, preferred day of the week, and most available phone numbers among others. The physician will then, examine the patients and request a baseline viral load.

Based on the physician's examination and findings, the Home Delivery Personnel (HDP) will deliver a three-month prepackaged ARV in a suitable package form with a patient identifier to the patient's chosen delivery point using a delivery motorcycle. The delivery points are chosen and the drugs are delivered in a way to ensure confidentiality. Patients in this arm will be advised to visit the hospital every six months for viral load and CD4+ cell count unless there is a problem requiring the physician's attention. Meanwhile, the HDP will be trained on how to interview these patients during the drug delivery using short structured

interview questions (see Fig. 4) while monitoring for adherence. The HDPs after each delivery reports back to the physician who then decides on whether to schedule the patient on appointment. Participants in this arm will be provided with a phone number to call in case of emergency or urgent consultation needs before the next appointment schedule.

On the other hand, the control group will receive their drugs in the HIV treatment hospital as usual but assess the viral load and CD4 count every six months as in the intervention group. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time.

Home delivery personnel training

The community health extension worker (CHEW) who will serve as the Home delivery Personnel (HDP) will undergo a 5-day training using the National ART training curriculum, World Health Organization (WHO) guideline on management of stigma, and WHO community home delivery manual. The HDPs were also trained on how to maintain utmost confidentiality when delivering the medication. The training will be carried out by an expert on HIV services.

Eligibility criteria

Inclusion criteria: All Stable patients who commenced ART for ≥ 6 months and have suppressed viral load.

Exclusion criteria

- i) Pregnancy at the time of enrollment
- ii) Age < 18 years
- iii) Defaulters
- iv) Unsuppressed viral load (>20 copies /ml)
- vi) Withdrawal of consent
- vii) Reside outside the state

Sample Size

Using a web-based sample size calculator,(27) and to demonstrate an HIV viral load suppression difference of ≤ 20 copies/ml between the control and the intervention arm between the baseline and 12 months and 24 months with a one-sided p-value of 0.05 and a power of 80%, a minimal sample size of 264 patients was deemed appropriate for each study group. To account for possible dropouts and loss to follow-up, an extra 20% of the calculated sample will be added to bring the number to a total of 316 patients of 158 patients per group.

Recruitment and retention

HIV patients that are eligible for the study will be recruited by the study personnel in the trial site (e.g. adherence officer or nurse). Each study participant will be assigned to an adherence officer (referred to in this trial as case managers) working in the HIV treatment hospital and participants will be tracked with their mobile phone numbers. The recruitment process is expected to last for 3 months.

Randomization

The two study sites will be considered as two clusters in the trial, in which patients in each cluster are randomized into treatment and control arm. Randomization will be done with the aid of a research randomizer, a web-based computer random-numbers generator (28). The randomization will be carried out by an independent person who is not part of the research team.

Outcomes

The primary outcome measure will be the difference between the HIV viral load suppression (≤ 20 copies/ml) between the baseline, 12 months, and 24 months in both the intervention and the control arms. The secondary outcome measure will include the pill count (it measures adherence), cost-effectiveness, and patient satisfaction. COBAS TaqMan 96 and the Amplilink software will be used to analyze viral load.

Time frame

April 26th, 2021 and it will end on May 10th, 2023(see fig 2)

LABORATORY ANALYSIS

Blood will be collected from the participants (10 mLs) into a vacutainer EDTA- specimen bottle. The EDTA-blood sample will be submitted to the virology laboratory at Nnamdi Azikiwe University Teaching Hospital for routine HIV-1 viral load testing by the CAP/CTM v20. The EDTA-sample tubes will undergo centrifugation at 145g for 25 minutes before the plasma separation into two phases in 2ml cryovials. The sample will be stored at -880C in an ultralow freezer. Manufacturer's instruction on the Roche CobadAmpliprep/ CobasTaqman (CAP/CTM) commercial kits will be used to measure the viral loads and the plasma HIV-1 RNA levels will be determined as copies/mL

The automatic extraction of the viral RNA will be done and then transferred to the COBAS TaqMan for amplification and detection. The CAP/CTM v2.0 will run along with the quantification range of the CAP/CTM v2.0 from 20 copies to 107copies/mL. Each run will consist of the test samples alongside high positive control, one low positive control, and one negative control from the kits. The result will be validated when the three controls have passed a run. CD4+ count analysis will be performed with the CD4+ easy count kit and the Partecyflow using the specifications as described by the manufacturer's manual. The result from the viral load is entered into a case report form (see. Fig5).

Patient and Public involvement

Patient involvement will be facilitated through contact with people living with HIV/AIDS (PLHA) support groups and HIV/ AIDS focal persons that are based in the study sites. A partnership will be established with three representatives from these groups and the research team. One member will be part of the Project organization, who will advise on study protocol (this includes protocol amendment) and will also participate in explaining the study to the participants in the simplest form, and feedback from the patients

will be noted. Two members will be involved as a member of the Project Steering Committee in the study procedures, especially those involving the recruitment and drug delivery process in a manner as to ensure strict confidentiality. One member will also participate in monitoring and evaluation (Data Monitoring Committee) of all the stages in the trial, where he/she will be allowed to comment on and help inform the improvement of the trial at any stage. The public will be involved during the dissemination of the research protocol.

Data Management

The research assistant is responsible for the collation and processing of the laboratory results, checklist for adherence, and case report form. To ensure confidentiality data will be protected by a password. The research assistant will carry out verification of the forms and capture them on the computer. The chairman of the data management team carries out data verification, data validation, queries data forms that may have issues. The major risk that may occur in this study is the exposure of patient personal information, to curtail this risk patient data will be treated with the utmost confidentiality. HDPs were instructed to seek privacy that is comfortable for the patient and himself before administering the medication and structured interview questions. All data will be collected and processed according to the guidelines on confidentiality established by the National Health Research Ethics Committee (NHREC). Unique identifiers and codes will be used to protect patient data which will be received by the data analyst and the principal investigator. Adverse events (AEs) will be documented and reported to the Data and Safety Monitoring Board and National Agency for Food and Drug Administration (NAFDAC) pharmacovigilance center. In the case of a serious adverse event (SAE), it will be reported to the Nnamdi Azikiwe University teaching hospital for further care, and the patient is withdrawn from the study.

Statistical analysis

Statistical analysis will be conducted using IBM SPSS for Windows, Version 25 (NY, USA; IBM Corp). The demographic characteristics (as well as outcomes) will be reported as means and standard deviation for

both the intervention and control arm. All the primary data will be analyzed using the intention-to-treat principle (to enable us to draw an unbiased conclusion about the effectiveness of our intervention) as well as per-protocol analysis. The latter will help identify how the treatment effect will be under optimal conditions. Logistic regression will be used to predict the factor of events in the primary outcome of this study (i.e., the percentage of participants' viral load suppression of ≤ 20 copies/mls). The balance of covariates will be analyzed by fixed-effects linear regression for continuous confounders (e.g., age) and fixed-effects binomial logistic regression for categorical confounders (e.g., gender). The effectiveness of the treatment will be tested according to patients' socio-demographics characteristics (age group [40–59 vs. 60–65 years], gender [male vs. female], viral load suppression (≤ 20 copies/mls) occupation [working vs. non-working] by conducting a stratified analysis of these covariates. Also, logistic regression will be used to estimate the effect of the treatment while taking into account the secondary outcomes (participants' viral load suppression of ≤ 20 copies/mls vs. adherence, cost-effectiveness, and patient satisfaction). The measure of effect will be the mean difference in outcomes will be derived by subtracting the baseline value from that of the last observation between the intervention and control groups. All statistical tests will be set at one-sided with an alpha level of 0.05.

The Cost-effectiveness of the 'home-based delivery' intervention will be assessed. Health resource use will be estimated from the health provider's perspective i.e. all costs incurred for providing the home-based delivery by a health service provider. Resource use items will include items such as staff time, consumables, cost of financial incentive, and equipment. All patient and family resources will be excluded. An activity-based costing method will be used to measure resource use. Data-capture questionnaires will be developed and sent to all the study personnel to record all their activities or resource use. Resource use items will then be multiplied by unit costs to determine a cost item. The entire cost item will be summed up and divided by the number of participants to determine the cost of the incentive scheme intervention per patient. Cost-effectiveness analysis alongside the randomized trial will be conducted to assess the cost per additional patient achieving viral suppression through the proposed intervention.

The incremental cost-effectiveness ratio (ICER) of 'Home delivery' over usual care will be calculated to determine the cost-effectiveness. Patient satisfaction will be evaluated by adopting a validated questionnaire to measure patient satisfaction.

Program steering committee (PSC)

The program steering committee's role in this trial is to monitor and evaluate all the steps in research. PSC consists of five members including two patient representatives whose sole responsibility in this trial is to offer surveillance for this research.

Data monitoring committee (DMC)

The data monitoring committee consists of an independent statistician, nurse, pharmacist, clinician, and patient. The DMC reviews the data and offers advice to other committees in the trial. The DMC will also coordinate the stopping of the trial when the data has been collected. The statistician will conduct a conditional power analysis of interim results or Bayesian predictive probabilities, [29] this will be done to identify if there is a significant difference between treatment groups and it will help the DMC make informed steps on how to end the trial. They will then communicate to the other trial committees to ensure that all aspect of disagreement is addressed before stopping the trial.

Audit

The last amendment to this protocol was made on 24th, April 2021 with a protocol amendment Number: 07. Modifications in the trial will be communicated to the editors for BMJ open journals, trial participants, and ethics committee and trial registries

DISCUSSION

The findings of this proposed trial should provide evidence on the prospect of delivering ARVs to patients in the comfort of their homes against what is currently obtainable in most health facilities in Nigeria is the

constant need to return to a healthcare facility for refill medications rather than a need for clinical monitoring by a nurse or physician (30). It is expected that the Home delivery model can improve patients' choice for care as well as minimizes interruption to patient's busy schedule (31,32), and possibly in other sub-Saharan African countries hence improving quality of care and patient satisfaction at the same time suppressing the patient viral load which is crucial for patient survival.

Ethics and dissemination:

Nnamdi Azikiwe University Teaching Hospital Health Research Ethics Committee (NAUTHHREC) approved this study (NAUTH/CS/66/VOL.13/VER III/23/2020/011). The trial will be conducted per the principles outlined in the Declaration of Helsinki. All identifiable data will be handled with the strictest confidentiality. Participants will be informed that they are free to withdraw at any time during any phase of the trial. Dissemination plans involve holding advocacy meetings with stakeholders in HIV care, publishing study outcome in an open-access peer-review journal (with an impact factor), and presentation of the outcome at an international conference.

Clinical trial registration

This trial is registered in the WHO International Clinical Trials Registry on 8th April 2020 through the WHO International Registry Network with the registration number, PACTR202004535536808.

Funding

This research did not receive whatsoever funding from government, private or cooperative institutions.

Competing interests

The authors declare that they have no competing interest

Abbreviations

AIDS: Acquired immunodeficiency syndrome

ARV: Antiretroviral therapy

HIV: Human immunodeficiency virus

CRT: Cluster Randomized trial

SPSS: Statistical Package for the Social sciences;

VL: Viral load

WHO: World Health Organization

SDG: Sustainable Developmental Goal

ICER: Incremental cost-effectiveness ratio

NACA: National Agency for Control of AIDS

UK: United Kingdom

SIDSHAS: Strengthening Integrated Delivery of Services on HIV/AIDS

CARC: Community Antiretroviral Refill Club

C-PARP: Community Pharmacy Antiretroviral Refill Programme

UNAIDS: United Nations Programme on HIV and AIDS

HAART: Highly Active Antiretroviral Therapy

HDP: Home delivery Personnel

PLHA: People living with HIV/AIDS

Acknowledgments:

We wish to acknowledge St. Charles Borromeo Specialists Hospital and Iyanu Missionary Hospital for their approval to use their hospital for the study site as well as the provision of the HDPs. Our special appreciation goes to the PLHA support group of St. Charles Borromeo Specialist Hospital and Iyanu Missionary Hospital for their support.

Availability of data and materials

The data used and/or analyzed during this study are available from the corresponding author on reasonable request.

Author contributions

NA, OE, and SN designed the trial. NA drafted the first protocol. All authors participated in reviewing the protocol. NA submitted the protocol for ethical clearance. All authors read and approved the final version of the protocol

REFERENCES

1. 90-90-90: treatment for all | UNAIDS. <https://www.unaids.org/en/resources/909090>. Accessed 21 Feb 2020.
2. Fast-Tracking HIV treatment; Parliamentary action and policy options|UNAIDS https://www.unaids.org/en/resouces/document/2015/2015_IPU_HIVTreatment. Accessed 21 Feb 2020.
3. Deeks SG, Lewin SR, Havlir D V. The end of AIDS: HIV infection as a chronic disease. Vol. 382, The Lancet. Lancet Publishing Group; 2013. p. 1525–33.
4. Right to health | UNAIDS. https://www.unaids.org/en/resources/documents/2017/20171120_right_to_health. Accessed 21 Feb 2020.
5. UNAIDS Issues New Fast-Track Strategy to End AIDS by 2030 – EGPAF <https://www.pedaids.org/2014/11/20/unaid-issues-new-fast-track-strategy-to-end-aids-by-2030>. Accessed 21 Feb 2020.
6. Right to health report |UNAIDS. https://www.unaids.org/en/20171120_right_to_health_report.

[Accessed 21 Feb 2020.](#)

7. Global HIV and Regional trend — 2019 | UNICEF. <https://data.unicef.org/topic/hivaids/global-regional-trends>. Accessed 21 Feb 2020.
8. GH0 | By category | Number of people (all ages) living with HIV - Estimates by WHO region. WHO. <https://apps.who.int/gho/data/view.main.22100?lang=en>. Accessed 21 Feb 2020.
9. New survey results indicate that Nigeria has an HIV prevalence of 1.4% | UNAIDS https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/march/20190314_nigeria. Accessed 22 Feb 2020.
10. Nigeria | UNAIDS. <https://www.unaids.org/en/regionscountries/countries/nigeria>. Accessed 22 Feb 2020.
11. Jaffar S, Amuron B, Foster S, Birungi J, Levin J, Namara G, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. *Lancet*. 2009;374(9707):2080–9.
12. WHO | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. WHO. 2018; <https://www.who.int/hiv/pub/arv/arv-2016/en/>. Accessed 22 Feb 2020.
13. Hontelez JAC, Chang AY, Ogbuaji O, De Vlas SJ, Barnighausen T, Atun R. Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa: Investment needs, population health gains, and cost-effectiveness. 2016 Sep 22];30(15):2341–50. <http://www.ncbi.nlm.nih.gov/pubmed/27367487>. Accessed 22 Feb 2020.
14. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa. *AIDS Care - Psychol Socio-Medical Asp AIDS/HIV*. 2007;19(5):658–65.
15. Cunningham WE, Andersen RM, Katz MH, Stein MD, Turner BJ, Crystal S, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. *Med Care*. 1999 Dec;37(12):1270–81.

- <http://www.ncbi.nlm.nih.gov/pubmed/10599608>. Accessed 22 Feb 2020.
16. Jalal-Eddeen Abubakar Saleh, Haruna Ismaila Adamu. Barriers to HIV/AIDS Treatment in Nigerian American Journal of Health Research.Vol.3, No. 5, 2015, pp. 305-309. doi 10.11648/j.ajhr.20150305.
 17. HIV/AIDS: Community models of care explained | MSF. <https://www.msf.org/hivaids-community-models-care-explained>. Accessed 22 Feb 2020
 18. Auld AF, Kamiru H, Azih C, Baughman AL, Nuwagaba-Biribonwoha H, Ehrenkranz P, et al. Evaluation of Swaziland's hub-and-spoke model for decentralizing access to antiretroviral therapy services. J Acquir Immune Defic Syndr. 2015;69(1):e1–12.
 19. Kolawole, Grace & Gilbert, Hannah & Dadem, Nancin & Genberg, Becky & Agaba, Patricia & Okonkwo, Prosper & Agbaji, Oche & Ware, Norma. (2017). Patient Experiences of Decentralized HIV Treatment and Care in Plateau State, North Central Nigeria: A Qualitative Study. AIDS Research and Treatment. 2017. 1-10. 10.1155/2017/2838059.
 20. Kolawole GO, Gilbert HN, Dadem NY, Genberg BL, Agaba PA, Okonkwo P, et al. Patient Experiences of Decentralized HIV Treatment and Care in Plateau State, North Central Nigeria: A Qualitative Study. AIDS Res Treat. 2017;2017.
 21. Agaba PA, Genberg BL, Sagay AS, Agbaji OO, Meloni ST, et al. (2018) Retention in Differentiated Care: Multiple Measures Analysis for a Decentralized HIV Care and Treatment Program in North Central Nigeria. J AIDS Clin Res 9: 756. doi: 10.4172/2155-6113.1000756.
 22. Selina Corkery Home delivery of anti-HIV drugs | aidsmap. <https://www.aidsmap.com/about-hiv/home-delivery-anti-hiv-drugs>. Accessed 5 Nov 2020
 23. Anambra (State, Nigeria) - Population Statistics, Charts, Map and Location <https://www.citypopulation.de/php/nigeria-admin.php?adm1id=NGA004>. Accessed 7 Nov 2020.
 24. Bashorun A, Nguku P, Kawu I, Ngige E, Ogundiran A, Sabitu K, et al. A description of HIV prevalence trends in Nigeria where is the problem? Pan Afr Med J. 2014;18:3.

25. NIGERIA PREVALENCE RATE – NACA Nigeria. <https://naca.gov.ng/nigeria-prevalence-rate/>. Accessed 22 Feb. 2020.
26. Ofoegbu CC, Okedo-Alex IN, Ilika AL, Ifeadike CC (2018) Awareness of Cardiovascular Diseases and Knowledge of Cardiovascular Risk Factors and Risk Reduction Measures among Urban and Rural Primary School Teachers in South-Eastern Nigeria. J Health Educ Res Dev 6: 289. doi: 10.4172/2380-5439.100028
27. Hulley SB, Cummings SR, Browner WS, Grady D, Newman TB. Designing clinical research : an epidemiologic approach. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. Appendix 6A, page 73.
28. Research Randomizer | Michelle A. Krieger <https://michellekrieger.wordpress.com/2018/09/08/research-randomizer/>. Accessed 8 Nov 202
29. Saville BR, Connor JT, Ayers GD, Alvarez J. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clin Trials. 2014;11:485–93.
30. Geldsetzer P, Francis JM, Ulena N, Sando D, Lema IA, Mboggo E, Vaikath M, Koda H, Lwezaula S, Hu J, Noor RA, Olofin I, Larson E, Fawzi W, Bärnighausen T. The impact of community health worker-led home delivery of antiretroviral therapy on virological suppression: a non-inferiority cluster-randomized health systems trial in Dar es Salaam, Tanzania. BMC Health Serv Res. 2017 Feb 22;17(1):160. doi: 10.1186/s12913-017-2032-7. PMID: 28228134; PMCID: PMC5322683.
31. Handerson Emily. News Medical Life Sciences. Offering a home delivery service for HIV medication can increase patient choice - [cited 2020 Sep 28]. Available from: www.news.medicnet>news>2021031
32. HIV/AIDS: Community models of care explained | MSF. [cited 2020 Feb 22]. Available from: <https://www.msf.org/hivaids-community-models-care-explained>

Fig 1 Randomization Outline

Fig 2. Trial Schedule

Study period																									
Month	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25
Enrolment																									
SCBH																									
Eligibility Criteria	x	x	x																						
Randomization			x																						
Informed consent	x	x	x																						
IMH																									
Eligibility Criteria	x	x	x																						
Randomization			x																						
Informed consent	X	x	x																						
Baseline Assessment																									
SCBH																									
Viral Load	X	x	x	x																					
Case form	x	x	x	x																					
IMH																									
Recruitment	x	x	x	X																					
Viral Load	X	x	x	x																					
Case form	x	x	x	x																					
Intervention																									
SCBH																									
ART Home delivery	X			X			X			x			X			x			X			X			
Structured interview	X			X			X			X			X			X			X			X			
Viral load assessment							X			X			X			X			X			X			
Case form	x			x			x			X			x			X			x			X			
IMH																									
ART Home delivery	X			X			X			X			X			x			X			x			
Structured interview	X			X			X			X			X			X			X			X			
Viral load assessment							X						X						X						
Case form	X			x			X			X			x			X			x			X			
Exit from trial																									
SCBH																									
ART Home delivery																									X
Structured interview																									X
Viral load assessment																									x
Case form																									X
IMH																									
ART Home delivery																									X
Structured interview																									X
Viral load																									X
Case form																									X

Fig 3: Informed consent form

FORM A

INFORMED CONSENT FORM

Name and Address/ Affiliation of Principal investigator:

AJAGU NNENNA, Department of Clinical Pharmacy and Pharmacy Management, 08035460931

Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Agulu Campus.

Nature of Research:

ASSESSING ANTIRETROVIRAL HOME DELIVERY MODEL AS AN OPTION TO IMPROVING ANTIRETROVIRAL ACCESSIBILITY IN NIGERIA. The study will be a cluster randomized trial. Two hospitals will be randomly selected one serving as control and the other assigned the intervention group. Participants become eligible by qualifying for the eligibility set criteria and agreeing to give written consent. The participants in each hospital are then allocated into either a control and intervention group randomly.

The benefit of the research to the participants:

This research will go a long way in improving convenience in access of stable HIV patient on medication because people living with HIV are faced with the challenges of overburdened HIV clinics in urban areas and cost of travelling to receive lifelong treatment, frequent visits to the hospitals for refills and lack of flexibility of HIV clinics to the work schedules of HIV patients. More so, improved access to ARVs will ensure that people living with HIV (PLWH) live a long and productive life, reduce disability-adjusted years (DALYs), as it is their right to have access to ARV(s) at any time they need it.

The benefit of research to society/ scientific world:

The findings of this proposed trial will provide evidence on the feasibility of initiating home delivery of the antiretroviral drugs to virally suppressed HIV clients. Findings will give a clue on the effectiveness and efficiency of the delivery strategy and whether it should be studied in other parts of Nigeria and possibly other sub-Saharan African countries.

Voluntarism:

Participation is purely voluntary participants can withdraw at any point of the investigation.

Confidentiality:

The researcher will uphold the confidentiality of the participants. Any form of information provided will be kept confidential.

Hazard (Trial Subject Safety):

There are no hazards that will affect or deform the subject, physically or emotionally. All personal data collection and processing will be carried out according to EU and national legislation. All study partners in the study site will be trained on the procedures for handling data during the study according to "Article 29 Data Protection Working Party". To ensure protection data, the data analyst will receive only key-coded data.

Right to withdraw:

The participant can decide to withdraw from this research at any time without any consequence. The result generated from this research will be published for academic purposes following ethical approval.

Consent:

Now that this study has been explained to me I fully understand the purpose and process involved, I am willing to volunteer myself to take part in this research.

Participant's Signature

Name of Participant _____

Signature/Thumb Print _____

Date _____

Phone Number _____

Investigator's / Assistants Signature

Fig. 4 checklist for the home delivery personnel

FORM C

CHECKLIST FOR THE HOME DELIVERY PERSONNEL

Trial Identification no.	
Sex	
Location	
Age	
Occupation	
Date	

A	General wellbeing	Tick please
1	Ask the client how he feels well today? (If the reply from the client is “not well” ask what the problem is)	
2	If the patient issue is related to any health condition like headache, fever, coughing, emotional distress, or any kind of illness (contact the hospital physician for instruction)	
3	Find out if the clients still participate in his/her routine activity like going to work, cooking, washing, etc. (If No, find out what might be the reason and contact the physician for advice)	
B	Side Effect of medication	
4	Find out if the clients experience any side effect with his/her medication (if yes, find out exactly what the patient experiences and contact the pharmacist)	
5	Find out if the drug affects the client’s daily activity in any way? (If yes, advice the patient according to your training)	
C	Pill Count	
6	Find out if client takes medication as directed(count the quantity left, if any)	
7	If medication is left check the reason why it is left	
8	If number 7, is as a result of non-adherence, side effect, or any form of negligence contact the pharmacist	
D	Routine care	
9	Ask the client if he remembers the date for his/her routine visit to the hospital (if no, remind him)	
10	Ask the client if she remembers the value of her last CD4 and Viral load and the implications(if no tell him the value and the implication)	
11	Thank the patient and remind him if he notices any issue of concern he should not hesitate to call	
12	Deliver the antiretroviral and tell him of the next visit	

Fig 5: Case Form

FORM B

CASE REPORT FORM

Trial ID number _____

Facility _____

Age _____ Sex: Male [] Female []

Date of commencement of HAART _____

Date of enrolment to the Trial _____

Date of issue of Drug _____

Informed Consent Obtained YES [] NO []

Clinical Data

HAART Regimen _____

Last reported viral load _____ copies/ml Date _____

Last reported CD4+ _____ copies/ml Date _____

Current viral load _____ copies/ml Date _____

Current CD4+ _____ copies/ml Date _____

Last reported pill count _____ copies/ml Date _____

Current pill count _____ copies/ml Date _____

Date of next refill _____ copies/ml Date _____

Health Care resource data

Use of checklist to access patient yes [] No []

Pharmacist comment on the ART Home delivery _____

Pan African Clinical Trials Registry

South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0506 / +27 21 938 0834 Fax: +27 21 938 0836
Email: pactradmin@mrc.ac.za Website: www.pactr.org

Trial no.:	PACTR202004535536808	Date of Approval:	08/04/2020
Trial Status:	Registered in accordance with WHO and ICMJE standards		

TRIAL DESCRIPTION

Public title	Home delivery of antiretroviral therapy in Nigeria
Official scientific title	Assessing home delivery model as an option to improving access to antiretroviral therapy in Nigeria; protocol for a cluster-randomized trial
Brief summary describing the background and objectives of the trial	Background: Continued access to antiretroviral agents is crucial to achieving the HIV/AIDS vision of controlling the viral epidemic by the year, 2030. Although different Antiretroviral agent delivery models have been explored in improving access to these agents in Nigeria, only 55% and 35% affected adults and children respectively are currently on these agents with an urgent need to scale up this access. This, therefore, underscores the need for the identification of newer models and strategies that will be effective in increasing access to ARV therapy in Nigeria. Objectives: This trial will be designed to evaluate the virologic outcome and cost-effectiveness of the home delivery model of antiretroviral agents. The study will also examine the willingness to pay for the services and the cost-benefit of the service to the care providers in Anambra State, Nigeria.
Type of trial	RCT
Acronym (If the trial has an acronym then please provide)	ARHD Trial
Disease(s) or condition(s) being studied	Infections and Infestations
Sub-Disease(s) or condition(s) being studied	HIV/AIDS
Purpose of the trial	Education /Training
Anticipated trial start date	20/06/2020
Actual trial start date	26/05/2021
Anticipated date of last follow up	10/05/2023
Actual Last follow-up date	10/08/2023
Anticipated target sample size (number of participants)	264
Actual target sample size (number of participants)	316
Recruitment status	Active, not recruiting
Publication URL	Non yet
Secondary Ids	Issuing authority/Trial register
	Issuing Authority/ Trial Register

STUDY DESIGN

Intervention assignment	Allocation to intervention	If randomised, describe how the allocation sequence was generated	Describe how the allocation sequence/code was concealed from the person allocating the participants to	Masking	If masking / blinding was used
--------------------------------	-----------------------------------	--	---	----------------	---------------------------------------

				the intervention arms		
Parallel: different groups receive different interventions at same time during study	Randomised	Simple randomization using a randomization table created by a computer software program		Sealed opaque envelopes	Masking/blinding used	Participants
INTERVENTIONS						
Intervention type	Intervention name	Dose	Duration	Intervention description	Group size	Nature of control
Experimental Group	Home Delivery of Antiretrovirals		2 years	Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and obtain a written consent the participant. Participants with signed consents will be sent to the physician who will examine the patients and request for a base line viral load. Based on the physician's examination and assessment findings, the Home Delivery Personnel(HDP) will deliver a three months ARV package to a chosen delivery point of choice (which may be home or a nearby place) by each of the patients in the intervention group. The delivery points are chosen and the drugs delivered in a way to ensure confidentiality. Patients in this arm are advised to visit the hospital every six months for viral load and CD4 cell count unless there is a problem requiring physician's attention. Meanwhile, the HDP will be trained on interviewing the patients on each day of delivery using short structured interviews while monitoring for adverse drug reaction, disease progression and adherence support. The HDP after each delivery reports back to the physician who then decides on whether to schedule the patient on appointment. On the other hand, the control group receives their drug in the facility as usual but assesses the viral load and CD4 count every six months as in the intervention group. The drugs to be delivered by the HDP will be prepackaged in suitable package with patients' identifiers and delivered to the patients using delivery motorcycle. The participant in the intervention arm is advised to contact a designated number (Nurse) if he/she notices any challenge before his next delivery date. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time.	158	
Control Group	Facility Delivery of Antiretroviral		2 years	The control group receives their drug(antiretrovirals) based on prescription in the facility as usual and assesses the viral load and CD4 count every six months.	158	Active-Treatment of Control Group
ELIGIBILITY CRITERIA						
List inclusion criteria	List exclusion criteria	Age Category	Minimum age	Maximum age	Gender	
i) Age ≥ 18years ii) Stable patients who commenced ART for ≥ 6months and have suppressed viral load iii) Reside within the State iv) Give informed consent	i) Pregnancy at time of the enrollment ii) Age < 18years iii) Newly commenced on ART iv) Defaulters v) Unsuppressed viral load (>20 copies /mil) vi) Withdrawal of consent vii) Reside outside the state	80 and over: 80+ Year, Adolescent: 13 Year-18 Year, Adult: 19 Year-44 Year, Aged: 65+ Year(s), Middle Aged: 45 Year(s)-64 Year(s)	18 Year(s)	85 Year(s)	Both	
ETHICS APPROVAL						
Has the study received appropriate ethics	Date the study will be	Date of approval	Name of the ethics committee			

committee approval		submitted for approval					
No		24/02/2020				Nnamdi Azikiwe Teaching Hospital Ethics Committee	
Ethics Committee Address							
Street address				City	Postal code	Country	
Nnamdi Azikiwe Teaching Hospital Nnewi				Nnewi	435101	Nigeria	

OUTCOMES		
Type of outcome	Outcome	Timepoint(s) at which outcome measured
Primary Outcome	Difference between the HIV viral loads of the two groups (≤ 20 copies /ml	12 months and 24 months
Secondary Outcome	The cost incurred in delivering care in both arms	12 months and 24 months
Secondary Outcome	Cost-effectiveness of home based delivery compared to facility based delivery	12 months and 24 months
Secondary Outcome	Client satisfaction with the services .	12 months and 24 months
Secondary Outcome	Willingness-to-pay for home based delivery	12 months and 24 months
Secondary Outcome	Adherence	at 3 month interval

RECRUITMENT CENTRES				
Name of recruitment centre	Street address	City	Postal code	Country
NACA approved HIV treatment centre	No 1 Limca Road Old Onitsha-Enugu Road, Onitsha and No 1 Km 3 Old Onitsha-Enugu Road, Ikenga Ogidi respectively	Onitsha and Ogidi	434221	Nigeria

FUNDING SOURCES				
Name of source	Street address	City	Postal code	Country
Nnenna Ajagu	NO. 12 Garden Avenue, Agbani.	Enugu		Nigeria

SPONSORS						
Sponsor level	Name	Street address	City	Postal code	Country	Nature of sponsor
Primary Sponsor	Nnamdi Azikiwe University	Awka-Enugu Express Way	Awka	5025	Nigeria	University

COLLABORATORS				
Name	Street address	City	Postal code	Country
Dr. Obinna Ikechukwu Ekwunife	Nnamdi Azikiwe University	Awka	5025	Nigeria
Dr Sunday Nduka	Nnamdi Azikiwe University	Awka	5025	Nigeria
Yohanna Avong	Institutue of Human Virology	Abuja		Nigeria

CONTACT PEOPLE				
Role	Name	Email	Phone	Street address
Principal Investigator	Ajagu Nnenna	ajagunnenna@yahoo.com	2348035460931	No. 8 Gardern Avenue Agbani
City	Postal code	Country	Position/Affiliation	
Enugu	0166610	Nigeria	Lecturer II	
Role	Name	Email	Phone	Street address
Scientific Enquiries	Nduka Sunday	so.nduka@unizik.edu.ng	2348033644385	Nnamdi Azikiwe University
City	Postal code	Country	Position/Affiliation	

Awka	5025	Nigeria	Senior Lecturer	
Role	Name	Email	Phone	Street address
Public Enquiries	Ekwunife Obinna	oi.ekwunife@unizik.ng	234706232501	Nnamdi Azikiwe University
City	Postal code	Country	Position/Affiliation	
Awka	5025	Nigeria	Senior Lecturer	

REPORTING				
Share IPD	Description	Additional Document Types	Sharing Time Frame	Key Access Criteria
Yes	The IPD will include participants demographic data, drug regime, viral load result and drug refill tracker	Statistical Analysis Plan, Study Protocol	IDP for our article will be available 3 months to 5 years following publication	The IDP and additional document will be available to clinical researchers who provide methodological sound proposal. The IDP should be used to achieve the aim of the proposal and the request should be directed to ajagunnenna@yahoo.com. A data access agreement has to be signed in order to gain access. Data will be available at http://www.ebhc-unizik.com/
URL	Results Available	Results Summary	Result Posting Date	First Journal Publication Date
http://www.ebhc-unizik.com/	No			
Result Upload 1:	Result Upload 2:	Result Upload 3:	Result Upload 4:	Result Upload 5:
Result URL Hyperlinks	Link To Protocol			
Result URL Hyperlinks				

Changes to trial information					
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Purpose of the trial	07/04/2020	it is actually a PhD project	Other Interventions	Education /Training
Section Name	Field Name	Date	Reason	Old Value	Updated Value
SecondaryID	SecondaryID List	07/04/2020	correction from reviewer		, Issuing Authority/ Trial Register
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Intervention	Intervention List	07/04/2020	Wrong input	Experimental Group, Home Delivery of Antiretrovirals, once every three months, Twenty four months, Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and obtain a written consent the participant. Participants with signed consents will be sent to the physician who will examine the patients and request for a base line viral load. Based on the physician's examination and	Experimental Group, Home Delivery of Antiretrovirals, , 2 years, Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and obtain a written consent the participant. Participants with signed consents will be sent to the physician who will examine the patients and request for a base line viral load. Based on the physician's examination and assessment findings, the Home Delivery Personnel(HDP) will deliver a three months ARV package to a chosen delivery point of choice (which may be home or a nearby place) by

				<p>assessment findings, the Home Delivery Personnel(HDP) will deliver a three months ARV package to a chosen delivery point of choice (which may be home or a nearby place) by each of the patients in the intervention group. The delivery points are chosen and the drugs delivered in a way to ensure confidentiality. Patients in this arm are advised to visit the hospital every six months for viral load and CD4 cell count unless there is a problem requiring physician's attention. Meanwhile, the HDP will be trained on interviewing the patients on each day of delivery using short structured interviews while monitoring for adverse drug reaction, disease progression and adherence support. The HDP after each delivery reports back to the physician who then decides on whether to schedule the patient on appointment. On the other hand, the control group receives their drug in the facility as usual but assesses the viral load and CD4 count every six months as in the intervention group. The drugs to be delivered by the HDP will be prepackaged in suitable package with patients' identifiers and delivered to the patients using delivery motorcycle. The participant in the intervention arm is advised to contact a designated number (Nurse) if he/she notices any challenge before his next delivery date. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time. , 31,</p>	<p>each of the patients in the intervention group. The delivery points are chosen and the drugs delivered in a way to ensure confidentiality. Patients in this arm are advised to visit the hospital every six months for viral load and CD4 cell count unless there is a problem requiring physician's attention. Meanwhile, the HDP will be trained on interviewing the patients on each day of delivery using short structured interviews while monitoring for adverse drug reaction, disease progression and adherence support. The HDP after each delivery reports back to the physician who then decides on whether to schedule the patient on appointment. On the other hand, the control group receives their drug in the facility as usual but assesses the viral load and CD4 count every six months as in the intervention group. The drugs to be delivered by the HDP will be prepackaged in suitable package with patients' identifiers and delivered to the patients using delivery motorcycle. The participant in the intervention arm is advised to contact a designated number (Nurse) if he/she notices any challenge before his next delivery date. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time. , 31,</p>
Section Name	Field Name	Date	Reason	Old Value	Updated Value

Intervention	Intervention List	07/04/2020	Wrong Input	Control Group, Facility Delivery of Antiretroviral, once in three months, twenty four months, the control group receives their drug in the facility as usual but assesses the viral load and CD4 count every six months as in the intervention group. The drugs to be delivered by the HDP will be prepackaged in suitable package with patients' identifiers and delivered to the patients using delivery motorcycle. The participant in the intervention arm is advised to contact a designated number (Nurse) if he/she notices any challenge before his next delivery date. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time. , 31, Dose Comparison	Control Group, Facility Delivery of Antiretroviral, , 2 years, The control group receives their drug(antiretrovirals) based on prescription in the facility as usual and assesses the viral load and CD4 count every six months. , 31, Active-Treatment of Control Group
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Outcome	OutCome List	07/04/2020	Wrong input	Primary Outcome, The primary outcome measure will be the difference between the HIV viral loads of the two sub-groups (≤ 20 copies /mL by 12months and 24 months). , by 12 months and 24 months	Primary Outcome, Difference between the HIV viral loads of the two groups (≤ 20 copies /ml , 12 months and 24 months
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Outcome	OutCome List	07/04/2020	Wrong input		Primary Outcome, Difference between the HIV viral loads of the two groups (≤ 20 copies /mL by 12months and 24 months)., 12 months and 24 months
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Outcome	OutCome List	07/04/2020	Wrong input	Secondary Outcome, (1) the cost incurred in delivering care in both arms; (2) cost-effectiveness of home based delivery compared to hospital based delivery measured by incremental cost-effectiveness ratio; (3) Willingness-to-pay for hospital based delivery; (4) client satisfaction with the services assessed using a standardized	Secondary Outcome, The cost incurred in delivering care in both arms;, 24 months

				questionnaire., 24 months	
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Outcome	OutCome List	07/04/2020	need to add relevant information		Secondary Outcome, The cost incurred in delivering care in both arms, 12 months and 24 months
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Outcome	OutCome List	07/04/2020	Need to add relevant point		Secondary Outcome, Cost-effectiveness of home based delivery compared to facility based delivery, 12 months and 24 months
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Outcome	OutCome List	07/04/2020	need to add relevant point		Secondary Outcome, Client satisfaction with the services assessed using a standardized questionnaire., 12 months and 24 months
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Outcome	OutCome List	07/04/2020	Need to add relevant points		Secondary Outcome, Willingness-to-pay for home based delivery, 12 months and 24 months
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Outcome	OutCome List	07/04/2020	wrong input	Secondary Outcome, Client satisfaction with the services assessed using a standardized questionnaire., 12 months and 24 months	Secondary Outcome, Client satisfaction with the services ., 12 months and 24 months
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Funding Source	FundingSources List	07/04/2020	Incomplete input		Nnenna Ajagu, NO. 12 Garden Avenue, Agbani., Enugu, , Nigeria, Self Funded,
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Sponsors	Sponsors List	07/04/2020	Wrong Input	Ajagu Nnenna, No 8, Gardern Avenue Agbani, Enugu, Enugu, 01660, Nigeria, Primary Sponsor, Individual,	Nnamdi Azikiwe University, Awka-Enugu Express Way, Awka, 5025, Nigeria, Primary Sponsor, University,
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Collaborators	Collaborators List	07/04/2020	Omission		Dr. Obinna Ikechukwu Ekwunife, Nnamdi Azikiwe University, Awka, 5025, Nigeria
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Collaborators	Collaborators List	07/04/2020	Omission		Dr Sunday Nduka, Nnamdi Azikiwe University, Awka, 5025, Nigeria
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Collaborators	Collaborators List	07/04/2020	Omission		Yohanna Avong, Institutue of Human Virology, Abuja, , Nigeria
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Reporting	Plan to share IPD	08/04/2020	As corrected by reviewers	Undecided	Yes

Section Name	Field Name	Date	Reason	Old Value	Updated Value
Reporting	IPD description	08/04/2020	As corrected by reviewers		The IPD will include participants demographic data, drug regime, viral load result and drug refill tracker
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Reporting	IPD-Sharing time frame	08/04/2020	Wrong input		IDP for our article will be available 3 months to 5 years following publication
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Reporting	Key access criteria	08/04/2020	wrong input		The IDP and additional document will be available to clinical researchers who provide methodological sound proposal. The IDP should be used to achieve the aim of the proposal and the request should be directed to ajagunnenna@yahoo.com . A data assess agreement has to be signed in other to gain assess. Data will be available at http://www.ebhc-unizik.com/
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Reporting	IPD URL	08/04/2020	wrong Input		http://www.ebhc-unizik.com/
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Reporting	Study protocol document	08/04/2020	As corrected by reviewers		Study Protocol, Statistical Analysis Plan
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Public title	08/04/2020	edit	Home delivery of antiretroviral in Nigeria	Home delivery of antiretroviral therapy in Nigeria
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Eligibility	Age group	08/04/2020	edit to include the full age range	80 and over: 80+ Year	Adolescent: 13 Year-18 Year, Adult: 19 Year-44 Year, Middle Aged: 45 Year(s)-64 Year(s), Aged: 65+ Year(s), 80 and over: 80+ Year
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Target no of participants	06/04/2021	Recommendation by Ethics committee (Nnamdi Azikiwe University Teaching Hospital Health Research Ethics Committee (NAUTHHREC) and Recommendation by BMJ Editor	62	264
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Final no of participants	06/04/2021	Recommendation by Ethics committee (Nnamdi Azikiwe University Teaching Hospital Health Research Ethics Committee	62	264

			(NAUTHHREC) and Recommendation by BMJ Editor		
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Intervention	Intervention List	06/04/2021	Recommendation by Ethics committee (Nnamdi Azikiwe University Teaching Hospital Health Research Ethics Committee (NAUTHHREC) and Recommendation by BMJ Editor	Experimental Group, Home Delivery of Antiretrovirals, , 2 years, Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and obtain a written consent the participant. Participants with signed consents will be sent to the physician who will examine the patients and request for a base line viral load. Based on the physician's examination and assessment findings, the Home Delivery Personnel(HDP) will deliver a three months ARV package to a chosen delivery point of choice (which may be home or a nearby place) by each of the patients in the intervention group. The delivery points are chosen and the drugs delivered in a way to ensure confidentiality. Patients in this arm are advised to visit the hospital every six months for viral load and CD4 cell count unless there is a problem requiring physician's attention. Meanwhile, the HDP will be trained on interviewing the patients on each day of delivery using short structured interviews while monitoring for adverse drug reaction, disease progression and adherence support. The HDP after each delivery reports back to the physician who then decides on whether to schedule the patient on appointment. On the other hand, the control group receives their drug in the facility as usual but assesses the viral load	Experimental Group, Home Delivery of Antiretrovirals, , 2 years, Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and obtain a written consent the participant. Participants with signed consents will be sent to the physician who will examine the patients and request for a base line viral load. Based on the physician's examination and assessment findings, the Home Delivery Personnel(HDP) will deliver a three months ARV package to a chosen delivery point of choice (which may be home or a nearby place) by each of the patients in the intervention group. The delivery points are chosen and the drugs delivered in a way to ensure confidentiality. Patients in this arm are advised to visit the hospital every six months for viral load and CD4 cell count unless there is a problem requiring physician's attention. Meanwhile, the HDP will be trained on interviewing the patients on each day of delivery using short structured interviews while monitoring for adverse drug reaction, disease progression and adherence support. The HDP after each delivery reports back to the physician who then decides on whether to schedule the patient on appointment. On the other hand, the control group receives their drug in the facility as usual but assesses the viral load

				and CD4 count every six months as in the intervention group. The drugs to be delivered by the HDP will be prepackaged in suitable package with patients' identifiers and delivered to the patients using delivery motorcycle. The participant in the intervention arm is advised to contact a designated number (Nurse) if he/she notices any challenge before his next delivery date. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time. , 31,	liberty to withdraw from the trial at any time. , 132,
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Intervention	Intervention List	06/04/2021	recommendation by Ethics committee (Nnamdi Azikiwe University Teaching Hospital Health Research Ethics Committee (NAUTHHREC) and BMJ Editor	Control Group, Facility Delivery of Antiretroviral, , 2 years, The control group receives their drug(antiretrovirals) based on prescription in the facility as usual and assesses the viral load and CD4 count every six months. , 31, Active-Treatment of Control Group	Control Group, Facility Delivery of Antiretroviral, , 2 years, The control group receives their drug(antiretrovirals) based on prescription in the facility as usual and assesses the viral load and CD4 count every six months. , 132, Active-Treatment of Control Group
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Intervention	Intervention List	15/04/2021	As per recommendation form ethics committee and BMJ editor	Experimental Group, Home Delivery of Antiretrovirals, , 2 years, Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and obtain a written consent the participant. Participants with signed consents will be sent to the physician who will examine the patients and request for a base line viral load. Based on the physician's examination and assessment findings, the Home Delivery Personnel(HDP) will deliver a three months ARV package to a chosen delivery point of choice (which may be home or a nearby place) by each of the patients in	Experimental Group, Home Delivery of Antiretrovirals, , 2 years, Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and obtain a written consent the participant. Participants with signed consents will be sent to the physician who will examine the patients and request for a base line viral load. Based on the physician's examination and assessment findings, the Home Delivery Personnel(HDP) will deliver a three months ARV package to a chosen delivery point of choice (which may be home or a nearby place) by each of the patients in the intervention group. The delivery points are chosen and the drugs delivered in a way to ensure confidentiality. Patients in this arm are advised to visit the hospital every six months for

				<p>the intervention group. The delivery points are chosen and the drugs delivered in a way to ensure confidentiality. Patients in this arm are advised to visit the hospital every six months for viral load and CD4 cell count unless there is a problem requiring physician's attention. Meanwhile, the HDP will be trained on interviewing the patients on each day of delivery using short structured interviews while monitoring for adverse drug reaction, disease progression and adherence support. The HDP after each delivery reports back to the physician who then decides on whether to schedule the patient on appointment. On the other hand, the control group receives their drug in the facility as usual but assesses the viral load and CD4 count every six months as in the intervention group. The drugs to be delivered by the HDP will be prepackaged in suitable package with patients' identifiers and delivered to the patients using delivery motorcycle. The participant in the intervention arm is advised to contact a designated number (Nurse) if he/she notices any challenge before his next delivery date. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time. , 132,</p>	<p>viral load and CD4 cell count unless there is a problem requiring physician's attention. Meanwhile, the HDP will be trained on interviewing the patients on each day of delivery using short structured interviews while monitoring for adverse drug reaction, disease progression and adherence support. The HDP after each delivery reports back to the physician who then decides on whether to schedule the patient on appointment. On the other hand, the control group receives their drug in the facility as usual but assesses the viral load and CD4 count every six months as in the intervention group. The drugs to be delivered by the HDP will be prepackaged in suitable package with patients' identifiers and delivered to the patients using delivery motorcycle. The participant in the intervention arm is advised to contact a designated number (Nurse) if he/she notices any challenge before his next delivery date. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time. , 135,</p>
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Intervention	Intervention List	15/04/2021	As per recommendation from ethics committee and BMJ editor	Control Group, Facility Delivery of Antiretroviral, , 2 years, The control group receives their drug(antiretrovirals) based on prescription in the facility as usual and assesses the viral load and CD4 count every six	Control Group, Facility Delivery of Antiretroviral, , 2 years, The control group receives their drug(antiretrovirals) based on prescription in the facility as usual and assesses the viral load and CD4 count every six months. , 135, Active-Treatment of Control Group

				months. , 132, Active-Treatment of Control Group	
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Outcome	OutCome List	15/04/2021	Recommendation by BMJ editor		Secondary Outcome, Adherence, at 3 month interval
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Final no of participants	16/04/2021	Recommendation by editor	264	270
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Official scientific title	24/04/2021	Corrected by BMJ editor.	Assessing home delivery model as an option to improving access to antiretroviral therapy in Nigeria; protocol for a randomized trial	Assessing home delivery model as an option to improving access to antiretroviral therapy in Nigeria; protocol for a cluster-randomized trial
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Trial description	24/04/2021	Typographical errors	Background: Continued access to antiretroviral agents is crucial to achieving HIV/AIDS vision of controlling the viral epidemic by the year, 2030. Although different Antiretroviral agents delivery models have been explored in improving access to these agents in Nigeria, only 55% and 35% affected adults and children respectively are currently on these agents with urgent need to scale up this access. This therefore underscores the need for identification of newer models and strategies that will be effective in increasing access to ARV therapy in Nigeria. Objectives: This trial will be designed to evaluate the virologic outcome and cost-effectiveness of home delivery model of antiretroviral agents. The study will also examine the willingness to pay for the services and the cost-benefit of the service to the care providers in Anambra State, Nigeria.	Background: Continued access to antiretroviral agents is crucial to achieving the HIV/AIDS vision of controlling the viral epidemic by the year, 2030. Although different Antiretroviral agent delivery models have been explored in improving access to these agents in Nigeria, only 55% and 35% affected adults and children respectively are currently on these agents with an urgent need to scale up this access. This, therefore, underscores the need for the identification of newer models and strategies that will be effective in increasing access to ARV therapy in Nigeria. Objectives: This trial will be designed to evaluate the virologic outcome and cost-effectiveness of the home delivery model of antiretroviral agents. The study will also examine the willingness to pay for the services and the cost-benefit of the service to the care providers in Anambra State, Nigeria.
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Anticipated trial start date	24/04/2021	Trial didn't take off on the initial agreed date.	12 May 2020	20 Jun 2020
Section Name	Field Name	Date	Reason	Old Value	Updated Value

Trial Information	Actual trial start date	24/04/2021	Trial didn't take off on the initial agreed date.	01 Jun 2020	26 May 2021
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Anticipated date of last follow up	24/04/2021	Corrected by Trial steering committee	10 Jun 2022	10 May 2023
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Completion date	24/04/2021	Corrected by Trial steering committee	10 Aug 2020	10 Aug 2023
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Trial Information	Final no of participants	24/04/2021	Corrected by Trial steering committee.	270	316
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Intervention	Intervention List	24/04/2021	Corrected by trial steering committee	Experimental Group, Home Delivery of Antiretrovirals, , 2 years, Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and obtain a written consent the participant. Participants with signed consents will be sent to the physician who will examine the patients and request for a base line viral load. Based on the physician's examination and assessment findings, the Home Delivery Personnel(HDP) will deliver a three months ARV package to a chosen delivery point of choice (which may be home or a nearby place) by each of the patients in the intervention group. The delivery points are chosen and the drugs delivered in a way to ensure confidentiality. Patients in this arm are advised to visit the hospital every six months for viral load and CD4 cell count unless there is a problem requiring physician's attention. Meanwhile, the HDP will be trained on interviewing the patients on each day of delivery using short structured interviews while monitoring for adverse drug reaction, disease progression and adherence support. The	Experimental Group, Home Delivery of Antiretrovirals, , 2 years, Enrolled participants will be directed to the research assistant responsible for introducing the study to the enrollees and obtain a written consent the participant. Participants with signed consents will be sent to the physician who will examine the patients and request for a base line viral load. Based on the physician's examination and assessment findings, the Home Delivery Personnel(HDP) will deliver a three months ARV package to a chosen delivery point of choice (which may be home or a nearby place) by each of the patients in the intervention group. The delivery points are chosen and the drugs delivered in a way to ensure confidentiality. Patients in this arm are advised to visit the hospital every six months for viral load and CD4 cell count unless there is a problem requiring physician's attention. Meanwhile, the HDP will be trained on interviewing the patients on each day of delivery using short structured interviews while monitoring for adverse drug reaction, disease progression and adherence support. The HDP will be prepackaged in

				HDP after each delivery reports back to the physician who then decides on whether to schedule the patient on appointment. On the other hand, the control group receives their drug in the facility as usual but assesses the viral load and CD4 count every six months as in the intervention group. The drugs to be delivered by the HDP will be prepackaged in suitable package with patients' identifiers and delivered to the patients using delivery motorcycle. The participant in the intervention arm is advised to contact a designated number (Nurse) if he/she notices any challenge before his next delivery date. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time. , 135,	suitable package with patients' identifiers and delivered to the patients using delivery motorcycle. The participant in the intervention arm is advised to contact a designated number (Nurse) if he/she notices any challenge before his next delivery date. Routine data will be collected and the patient is at liberty to withdraw from the trial at any time. , 158,
Section Name	Field Name	Date	Reason	Old Value	Updated Value
Intervention	Intervention List	24/04/2021	Recommendation by trial steering committee	Control Group, Facility Delivery of Antiretroviral, , 2 years, The control group receives their drug(antiretrovirals) based on prescription in the facility as usual and assesses the viral load and CD4 count every six months. , 135, Active-Treatment of Control Group	Control Group, Facility Delivery of Antiretroviral, , 2 years, The control group receives their drug(antiretrovirals) based on prescription in the facility as usual and assesses the viral load and CD4 count every six months. , 158, Active-Treatment of Control Group